Therapeutic Targets for Adrenocortical Carcinoma in the Genomics Era

Overview

Journal J Endocr Soc

Specialty Endocrinology

Date 2018 Nov 8

PMID 30402590

Citations 25

Authors

Dipika R Mohan

Antonio Marcondes Lerario

Gary D Hammer

Affiliations

Soon will be listed here.

Abstract

Adrenocortical carcinoma (ACC) is a rare and often fatal cancer, affecting ~1 person per million per year worldwide. Approximately 75% of patients with ACC eventually develop metastases and progress on the few available standard-of-care medical therapies, highlighting an incredible need for an improved understanding of the molecular biology of this disease. Although it has long been known that ACC is characterized by certain histological and genetic features ( high mitotic activity, chromosomal instability, and overexpression of ), only in the last two decades of genomics has the molecular landscape of ACC been more thoroughly characterized. In this review, we describe the findings of historical genetics and recent genomics studies on ACC and discuss how underlying concepts emerging from these studies contribute to the current model of critical pathways for adrenocortical carcinogenesis. Integrative synthesis across these studies reveals that ACC consists of three distinct molecular subtypes with divergent clinical outcomes and implicates differential regulation of Wnt signaling, cell cycle, DNA methylation, immune biology, and steroidogenesis in ACC biology. These cellular programs are pharmacologically targetable and may enable the development of therapeutic strategies to improve outcomes for patients facing this devastating disease.

Citing Articles

A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples.

Arakawa Y, Elloumi F, Varma S, Khandagale P, Jo U, Kumar S Cancer Res Commun. 2024; 4(9):2384-2398.

PMID: 39162009 PMC: 11389377. DOI: 10.1158/2767-9764.CRC-24-0100.

Advances in translational research of the rare cancer type adrenocortical carcinoma.

Ghosh C, Hu J, Kebebew E Nat Rev Cancer. 2023; 23(12):805-824.

PMID: 37857840 DOI: 10.1038/s41568-023-00623-0.

The Characteristics of Tumor Microenvironment Predict Survival and Response to Immunotherapy in Adrenocortical Carcinomas.

Lai G, Liu H, Deng J, Li K, Zhang C, Zhong X Cells. 2023; 12(5).

PMID: 36899891 PMC: 10000893. DOI: 10.3390/cells12050755.

Pediatric adrenocortical carcinoma.

Ilanchezhian M, Varghese D, Glod J, Reilly K, Widemann B, Pommier Y Front Endocrinol (Lausanne). 2022; 13:961650.

PMID: 36387865 PMC: 9659577. DOI: 10.3389/fendo.2022.961650.

Was It an Adrenocortical Adenoma or an Adrenocortical Carcinoma? Limitation of the Weiss Scoring System in Determining the Malignant Potential of Adrenocortical Tumor: Report on Two Cases.

Wong C, Fok C, Chan Y, Tam V, Fung L Case Rep Endocrinol. 2022; 2022:7395050.

PMID: 36160179 PMC: 9492358. DOI: 10.1155/2022/7395050.

References

Varghese J, Habra M . Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes. 2017; 24(3):208-214. DOI: 10.1097/MED.0000000000000332. View

Borges K, Andrade A, Silveira V, Antonio D, Vasconcelos E, Antonini S . The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line. Anticancer Drugs. 2017; 28(6):634-644. DOI: 10.1097/CAD.0000000000000504. View

Kroiss M, Sbiera S, Kendl S, Kurlbaum M, Fassnacht M . Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. Horm Cancer. 2016; 7(5-6):345-355. PMC: 10355952. DOI: 10.1007/s12672-016-0273-2. View

Heaton J, Wood M, Kim A, Lima L, Barlaskar F, Almeida M . Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol. 2012; 181(3):1017-33. PMC: 3432433. DOI: 10.1016/j.ajpath.2012.05.026. View

De Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R . Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2004; 90(3):1819-29. DOI: 10.1210/jc.2004-1075. View

Hao H, Xie Y, Zhang Y, Charlat O, Oster E, Avello M . ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature. 2012; 485(7397):195-200. DOI: 10.1038/nature11019. View

Reincke M, Karl M, Travis W, Mastorakos G, Allolio B, Linehan H . p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab. 1994; 78(3):790-4. DOI: 10.1210/jcem.78.3.8126158. View

Gortz B, Roth J, Speel E, Krahenmann A, de Krijger R, Matias-Guiu X . MEN1 gene mutation analysis of sporadic adrenocortical lesions. Int J Cancer. 1999; 80(3):373-9. DOI: 10.1002/(sici)1097-0215(19990129)80:3<373::aid-ijc7>3.0.co;2-b. View

Suh I, Weng J, Fernandez-Ranvier G, Shen W, Duh Q, Clark O . Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells. Arch Surg. 2010; 145(3):226-32. PMC: 3478887. DOI: 10.1001/archsurg.2009.292. View

10.

Libe R, Groussin L, Tissier F, Elie C, Rene-Corail F, Fratticci A . Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007; 13(3):844-50. DOI: 10.1158/1078-0432.CCR-06-2085. View

11.

Lerario A, Moraitis A, Hammer G . Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol. 2013; 386(1-2):67-84. PMC: 3943605. DOI: 10.1016/j.mce.2013.10.028. View

12.

Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere A . Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005; 65(17):7622-7. DOI: 10.1158/0008-5472.CAN-05-0593. View

13.

Wasserman J, Novokmet A, Eichler-Jonsson C, Ribeiro R, Rodriguez-Galindo C, Zambetti G . Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol. 2015; 33(6):602-9. PMC: 4517369. DOI: 10.1200/JCO.2013.52.6863. View

14.

Koo B, van Es J, van den Born M, Clevers H . Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia. Proc Natl Acad Sci U S A. 2015; 112(24):7548-50. PMC: 4475934. DOI: 10.1073/pnas.1508113112. View

15.

Barlaskar F, Spalding A, Heaton J, Kuick R, Kim A, Thomas D . Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab. 2008; 94(1):204-12. PMC: 2630877. DOI: 10.1210/jc.2008-1456. View

16.

Ohgaki H, Kleihues P, Heitz P . p53 mutations in sporadic adrenocortical tumors. Int J Cancer. 1993; 54(3):408-10. DOI: 10.1002/ijc.2910540310. View

17.

Barzon L, Chilosi M, Fallo F, Martignoni G, Montagna L, Palu G . Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol. 2001; 145(2):207-12. DOI: 10.1530/eje.0.1450207. View

18.

Kiseljak-Vassiliades K, Zhang Y, Kar A, Razzaghi R, Xu M, Gowan K . Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. Endocrinology. 2018; 159(7):2532-2544. PMC: 6669820. DOI: 10.1210/en.2018-00310. View

19.

Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F . Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015; 100(3):841-9. DOI: 10.1210/jc.2014-3182. View

20.

Roca E, Berruti A, Sbiera S, Rapa I, Oneda E, Sperone P . Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer. Endocr Relat Cancer. 2017; 24(7):319-327. DOI: 10.1530/ERC-17-0095. View